BIGBEAR
PHARMACEUTICAL
Tucatinib specifically targets the HER2 protein and inhibits tumor cell proliferation and growth by blocking its signaling pathways.
AuthenticGuaranteeFast DeliveryPrivacy Seattle Genetics recently announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with trastuzumab and capec···【More】
Update: 27 Mar,2026Source: BigbearViews: 142
Seattle Genetics recently announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with trastuzumab and capec···【More】
Update: 27 Mar,2026Source: BigbearViews: 145
On April 17, 2020, the U.S. Food and Drug Administration (FDA) approved the new breast cancer drug Tukysa in combination with trastuzumab (Herceptin) ···【More】
Update: 27 Mar,2026Source: BigbearViews: 159
On July 2, 2022, Seagen announced the full results of the pivotal Phase 2 MOUNTAINEER trial, demonstrating that tucatinib (trademark: TUKYSA) in combi···【More】
Update: 27 Mar,2026Source: BigbearViews: 151
Product Profile and Unmet Medical NeedTukysa (tucatinib) is an oral tyrosine kinase inhibitor of the HER2 protein, approved in 36 countries. Currently···【More】
Update: 23 Mar,2026Source: BigbearViews: 152
Trial Announcement and PresentationOn July 2, 2022, Seagen announced full results from the pivotal Phase 2 MOUNTAINEER trial, which showed that tucati···【More】
Update: 23 Mar,2026Source: BigbearViews: 163
Milestone in Targeted Therapy for Colorectal CancerSeagen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated ···【More】
Update: 23 Mar,2026Source: BigbearViews: 145
Targeted Oral Therapy for HER2-Positive MalignanciesSeattle Genetics, Inc. has announced the U.S. Food and Drug Administration (FDA) approval of Tukys···【More】
Update: 23 Mar,2026Source: BigbearViews: 133
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
